An observational study in Malaria, Schistosomiasis and Hiv Infection, sponsored by Radboud University Medical Center. Completed at 1 site in Uganda. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-04.
Sponsored by Radboud University Medical Center · Observational
A longitudinal study on immune responses in relation to protection against clinical malaria episodes will be conducted in Apac District, Uganda. Three cohorts will be recruited: children 1 to 5 years of age (n=250), children 6 to 10 years of age (n=125) and adults 25 and above (n=125). After finger prick sampling (\~300µL) and examination at enrolment, participants will be followed up for one year. Follow-up will include fortnightly active case detection and three-monthly cross-sectional surveys. Clinical malaria attacks and the associated clinical and parasitological parameters will be related to immunological profiles determined utilizing a protein microarray as a capture substratum to profile the humoral immune response against a vast number of parasite antigens.
For individuals who experience a clinical malaria attack or who are diagnosed with high density parasitaemia (≥15,000 parasites/µL) during cross-sectional surveys, a 5mL blood sample is obtained to determine the diversity of parasite antigens in the population in relation to antigen recognition in the cohort.
1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.
This study's planned enrollment of 500 is below the median of 600 across 218 observational studies indexed under Malaria.
Browse Malaria studies →Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Randomly selected individuals living in Abedi, Apac District, Uganda.
Exclusion Criteria:
Immune correlates of protection against clinical malaria episodes with plasmodium falciparum
IMMUNE RESPONSES: protein array. CLINICAL MALARIA EPISODES: (reported) fever with i) P. falciparum parasites; ii) ... at a density \>=5,000 parasites/ul; iii) ... at a density \>=10,000 parasites/ul IMMUNOLOGICALLY PROTECTED INDIVIDUALS: parasitaemic during follow-up without reporting to the health facility with indicators of a clinical malaria episode
Geographical patterns in malaria morbidity
Households are geo-located by GPS and hotspots of malaria transmission will be determined and related to serological profiles.
Asymptomatic parasite carriage and immune responses in different age-groups exposed to intense malaria transmission
ASYMPTOMATIC PARASITE CARRIAGE will be confirmed by microscopy and PCR.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center